GlassScriptPhysician profile
Raul Romea
NPI 1962408112
$7,523.08
in general payments reported to CMS, 2019-2025
38 companies · $2,289 in 2025
The $2,289 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,444 · 2020: $517 · 2021: $252 · 2022: $381 · 2023: $893 · 2024: $1,747 · 2025: $2,289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,851 · Education: $77.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,851.30 |
| Education | $77.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,967.74 | 2019-2025 | Evenity, Enbrel, Krystexxa |
| Abbvie INC. | $914.76 | 2019-2025 | Rinvoq, Skyrizi |
| Pfizer INC. | $656.18 | 2019-2025 | |
| Aurinia Pharma U.S., INC. | $429.20 | 2021-2025 | Lupkynis |
| Novartis Pharmaceuticals Corporation | $416.07 | 2019-2025 | |
| Ucb, INC. | $398.02 | 2019-2025 | Cimzia, Bimzelx |
| Fresenius Kabi USA, LLC | $364.78 | 2023-2025 | Idacio, Adalimumab-Aacf, Tyenne |
| E.R. Squibb & Sons, L.L.C. | $303.48 | 2019-2025 | Orencia |
| Boehringer Ingelheim Pharmaceuticals, INC. | $214.17 | 2023-2025 | Ofev, Jardiance, Cyltezo |
| Glaxosmithkline, LLC. | $179.72 | 2019-2025 | Benlysta, Shingrix |
| Octapharma USA, INC. | $176.70 | 2023-2025 | Octagam Immune Globulin (Human), Panzyga |
| Janssen Biotech, INC. | $172.83 | 2019-2025 | Tremfya, Simponi Aria |
| Genentech USA, INC. | $164.61 | 2019-2025 | Actemra, Gazyva |
| Genzyme Corporation | $131.35 | 2019-2025 | |
| Celgene Corporation | $110.66 | 2019 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Romea listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.